…ols) were not effective in epilepsy and other seizure disorders (Bilbao et al. BMC Med 2022;20:259). The authors cautioned against recreational marijuana use to treat seizures. Marijuana contains delta-9-tetrahydrocannabinol (THC). The efficacy of THC has not been demonstrated in seizure disorders and there are conflicting data on whether it has pro- or antiseizure effects….
…ated worsening (SAW) (https://gavingiovannoni.substack.com/p/does-burnt-out-ms-exist). SAW was largely equated with paramagnetic rim lesions (PRL), although PRLs are not detectable in many MS patients (Kwong et al. PLoS One 2021;16:e0256845). Moreover, it is likely that PRLs, which are characterized by deposition of iron-rich microglia/macrophages and remyelination failure, do not fully capture the breadth and heterogeneity of progressive biology….
Most patients with epilepsy become seizure-free during treatment with antiseizure medications (ASM) and current guidelines by the American Academy of Neurology (AAN) support ASM discontinuation in some individuals to reduce the side effect burden and improve quality of life (Gloss et al. Neurology 2021;97:1072-1081). Online calculators enable clinicians to estimate the seizure risk after ASM withdrawal (http://epilepsypredictiontools.info/aedwith…
…res were associated with higher EDSS scores, Timed 25-Foot Walk times and 9-Hole Peg Test times. Higher NfL levels were also associated with greater disease severity. GFAP Z scores were similar across treatment categories. In contrast, lower NfL concentrations were found in progressive patients treated with monoclonal antibodies. In the subset for whom MRIs were available, higher GFAP and NfL Z scores were associated with a higher T2 lesion count….
…the four weeks after vaccination in NMOSD patients (Fam et al. EAN 2024;EPO-776). Data were obtained from the PREVENT trial of eculizumab and the CHAMPION-NMOSD trial of ravulizumab. In PREVENT, 3.1% in the eculizumab group and 10.6% in the placebo group had a relapse. In CHAMPION-NMOSD, the relapse rate was 2.9%. The authors noted that it has not been determined if relapses were attributable to vaccination or to an inherent risk among NMOSD patie…